Radiofrequency Ablation in Lung Cancer: Promising Results in Safety and Efficacy
Radiofrequency Ablation in Lung Cancer: Promising Results in Safety and Efficacy
Only about 15% of patients diagnosed with lung carcinoma each year are surgical candidates, either due to advanced disease or comorbidities. The past decade has seen the emergence of minimally invasive therapies using thermal energy sources: radiofrequency, cryoablation, focused ultrasound, laser, and microwave; radiofrequency ablation (RFA) is the best developed of these. Radiofrequency ablation is safe and technically highly successful in terms of initial ablation. Long-term local control or complete necrosis rates drop considerably when tumors are larger than 3 cm, although repeat ablations can be performed. Patients with lung metastases tend to fare better with RF lung ablation than those with primary lung carcinoma in terms of local control, but it is unclear if this is related to smaller tumor size at time of treatment, lesion size uniformity, and sphericity with lung metastases, or to differences in patterns of pathologic spread of disease. The effects of RFA on quality of life, particularly dyspnea and pain, as well as long-term outcome studies are generally lacking. Even so, the results regarding RF lung ablation are comparable to other therapies currently available, particularly for the conventionally unresectable or high-risk lung cancer population. With refinements in technology, patient selection, clinical applications, and methods of follow-up, RFA will continue to flourish as a potentially viable stand-alone or complementary therapy for both primary and secondary lung malignancies in standard and high-risk populations.
After 52 pack-years of smoking, Don had little to celebrate on his 70th birthday when he was diagnosed with stage IB non-small-cell lung carcinoma. To make matters worse, he was told that, despite his early-stage cancer, he was not a suitable candidate for surgical resection due to his extensive lung disease. Bereft of his most promising option, Don was left without much hope. Although not a candidate for surgery, Don did indeed have other options, many of which would not have been available to him had he been diagnosed a decade earlier. Don did eventually undergo radiofrequency ablation (RFA) of his lung cancer and has just celebrated his 75th birthday. Lung carcinoma remains the leading cause of cancer death in the United States. Over the past decade, lung cancer death rates have more than quadrupled, from 5.4 to 29.4 per 100,000. The American Cancer Society estimates that in 2005 the number of lung cancer deaths will rise to 163,510-90,490 men and 73,020 women-accounting for 28% of all cancer-related deaths. The number of newly diagnosed lung cancers will rise to 172,570, or 93,010 new cases in men and 79,560 in women.[ 2] Nearly 60% of those diagnosed with lung cancer die within 1 year of their diagnosis and nearly 75% within 2 years. Despite recent advances in therapy, the relative 5-year survival rate for all stages of lung cancer has improved only slightly to 15%. For early-stage lung carcinoma, surgical resection confers the best survival option, with 5-year survival rates approaching 80% for stage I disease and 40% for stage II disease. Only about 15% of patients diagnosed with lung carcinoma each year are surgical candidates. Most patients present with advanced or widespread disease at the time of diagnosis and, therefore, are not considered candidates for surgery. Some patients have technically resectable disease but cannot undergo surgery because of comorbid cardiopulmonary disease. This population represents a suitable target for novel, minimally invasive lung-sparing therapies providing local control. Local therapy may also be appropriate in limited metastatic disease. The lung is the second most frequent site of metastatic disease. Surgical resection, or metastasectomy, appears to confer some survival benefits in carefully selected patients. Although it is somewhat uncertain whether this benefit results from total- body tumor burden cytoreduction or a less aggressive natural course of disease in this patient subpopulation, pulmonary metastasectomy is increasingly accepted as treatment in selected patients, with a 10-year survival rate of approximately 25%. At least 90% of the 10-year survivors remain free of disease. Yet the size and number of metastatic nodules frequently preclude attempts at surgical resection. Since the majority of patients develop disease recurrence following metastasectomy, and repeated resections can remove significant amounts of functioning lung, this patient population also represents a suitable target for minimally invasive lung-sparing therapies. Since the early 1990s, an increasing number of minimally invasive techniques have been introduced into clinical practice in the treatment of primary and secondary pulmonary malignancy. Image-guided interventional and video-assisted thoracoscopic approaches have become attractive alternatives to open thoracic surgical resection. The past decade has seen the emergence of minimally invasive therapies using thermal energy sources: radiofrequency, cryoablation, focused ultrasound, laser, and microwave. Radiofrequency ablation is the best developed, secondary to the advent of bipolar and multielectrode and internal tip-cooling RF electrodes as well as advances in computed-tomography (CT) technology. Radiofrequency ablation is a controlled electrosurgical technique that implements high-frequency alternating current to generate localized electromagnetic fields, heating targeted tissues to desiccation, or thermal coagulation. Naturally, cells of targeted tissue die when exposed to high thermal doses. For a variety of reasons, including less efficient heat dissipation, the cells of neoplastic tissues are more sensitive to heat effects than are cells of healthy tissues. Thus, RFinduced hyperthermia exploits this difference in heat sensitivity by creating localized temperature increases in neoplastic tissues to greater than 57C to 60C, while restricting temperatures in healthy tissues to normal ranges.[ 8] Several authors have advocated that lung tumors are well suited to RFA because of the so-called "oven effect," whereby the air (high resistance) surrounding an intraparenchymal tumor (low resistance) affords an insulating effect and traps heat within the targeted tumor. Well established in the treatment of various cardiac and neurologic dysfunctions, RFA has faced a major barrier to further application: the small lesion size created by earlier generation devices and delivery methods. The advent of bipolar and multielectrode and tip-cooled RF electrodes, enabling the creation of larger areas of controlled and reproducible necrosis in animal and human models in vitro and in vivo, has expanded potential clinical applications to include tumor therapy- notably in the treatment of primary and secondary brain and hepatic malignancies.[11,12] The feasibility and safety of percutaneous interstitial thermal ablation of pulmonary tissue have also been investigated. Using a percutaneous CT-guided transthoracic technique, Goldberg et al showed that RFA was not only performed safely in the pulmonary tissue of rabbits but that tissue response to thermal injury was controlled, predictable, and easily monitored.[ 9] Subsequent investigation has been directed to the ablation of abnormal tissue within the pulmonary parenchyma, specifically malignancy. Since 1996, several authors have used CT-guided RF application to successfully treat induced sarcomas within the lungs of rabbit, canine, and ovine models, characterizing tissue changes following lung ablation with at least 95% necrosis to complete eradication of treated tumor nodules at histopathologic analysis and demonstrating the influence of surrounding tissue on ablation outcome.[13-17] Complications recorded during these studies include pneumothorax, pulmonary hemorrhage, and tumor relapse. Patient Selection No solid or strict criteria currently exist regarding patient appropriateness for undergoing RFA. For primary lung carcinoma, much of the current literature focuses on the unresectable or high-risk group.[18-26] These patients have early-stage lung carcinomas that could qualify for surgical resection but are medically inoperable because of comorbid cardiopulmonary disease, particularly severe chronic obstructive pulmonary disease or inability to withstand lung loss. Other relevant populations have limited local recurrence following primary treatment, have refused surgical intervention, seek palliation such as pain control, or desire cytoreduction to render more feasible complementary therapy such as radiation using a smaller field. In any scenario, all imaging-CT, PET, and/or PET/CT-should demonstrate localized disease without hilar or mediastinal nodal and extrathoracic involvement. Radio-graphic staging is limited in its description of the full extent of disease, particularly in groups in whom mediastinoscopy and lymph node sampling cannot be performed due to the high risk of general anesthesia. Even in the best-case scenario, disease is likely to be understaged by imaging alone. Solid or strict criteria are also lacking for tumor characteristics favorable for RFA, although trends are beginning to emerge. "Ideal" lesion features include solitary status. But multiple lesions are considered if they are fewer than five in number, completely intraparenchymal, smaller than 5 cm (more appropriately 3 cm), confined within a single ablation zone, spherical vs irregular, and noncontiguous with the hila and its large airways and pulmonary arteries and veins, or the mediastinum or vital structures within such as the trachea, esophagus, heart, aorta, and great arteries. Akeboshi et al achieved lower rates of complete necrosis in those targeted lesions greater than 3 cm, and Lee et al found that lower rates of control correlated with decreased mean survival rates: 8.7 vs 19.7 months for the complete necrosis group. As with hepatic tumor ablation, tumors close to large arteries and veins are often incompletely ablated, owing to the heatsink effect.[28,29] Tumors close to the hilum likely already have regional nodal involvement. Technique and Delivery Radiofrequency ablation systems approved by the US Food and Drug Administration for coagulation necrosis of soft-tissue tumors have three components: an RF generator, an active electrode, and dispersive electrodes. Radiofrequency energy is introduced into the tissue via the active electrode. As this alternating current moves from the active to the dispersive electrode (ie, electrosurgical return pad) and then back to the active electrode, the ions within the tissue oscillate in an attempt to follow the change in the direction of the alternating current. This movement results in frictional heating of the tissue, and as the temperature within the tissue rises beyond 60C, cells begin to die. This phenomenon creates the region of necrosis surrounding the electrode. Radiofrequency ablation has mostly been performed as an outpatient procedure, usually under conscious sedation. Operators have at times favored deep conscious sedation and even general anesthesia, however, particularly in patients with targeted lesions on the pleura and/or chest wall, and especially in those seeking palliation for pain. As with most interventional procedures, intravenous access is established and blood pressure, heart rate and rhythm, and oxygen saturation are continuously monitored. Because all delivered electrical current must be grounded, RF devices require application of two or four grounding pads to the chest wall or thighs, and proper contact of the electrode gel sometimes necessitates the shaving of body hair. Some authors have advocated prophylactic antibiotics, particularly in the ablation of masses greater than 5 cm, due to the ensuing large volume of necrosis. All intended tumors targeted for RFA should have histopathologic confirmation. Conventional CT with incremental scanning or CT fluoroscopy is used to localize the target tumor. Following standard sterile preparation and draping, 1% lidocaine hydrochloride is administered as local anesthesia intradermally and into the deeper subcutaneous and muscular tissue tract. At this juncture, at least two approaches have been used. Some authors favor placement of a localization needle, such as a 20- or 22-gauge Chiba or spinal needle, with subsequent placement of the RF electrode via tandem needle technique, and others favor direct placement of the RF electrode. The former approach is more practical under conventional scanning. Available Systems Currently, four generator and electrode systems from four different manufacturers are available:
- Boston Scientific (formerly Radiotherapeutics) RF-3000 generator and LeVeen and Concerto multitined expandable needle electrodes
- RITA (RF interstitial tissue ablation) system with 1500X electrosurgical generator and StarBurst SDE, Semi-Flex, XL, and XLi multitined expandable electrodes
- Valleylab (formerly Radionics) Cool-tip RF Ablation System with internally cooled single and clustered needle electrodes, the three-needle array spaced 0.5 cm apart
- Berchtold Elektrotom 106 HiTT with open-perfused electrodes.
In order to optimally deliver a consistent, homogenous, and reproducible area of thermal ablation, Boston Scientific and RITA employ multitined expandable electrode design configurations, while Valleylab opts for single- or clustered-needle electrodes that rely on internal cooling to decrease surrounding tissue impedance, allowing for maximum energy deposition. Similarly, Berchtold uses single- or dual-needle electrodes to deliver RF energy. Although both the Boston Scientific LeVeen and RITA StarBurst XL and XLi expandable array electrodes feature tines that are incrementally deployed to the ablation size required, the LeVeen electrode employs 10 tines in a more horizontal, or "daisy," configuration, while the StarBurst uses a more vertical, or "Christmas tree," configuration. Each manufacturer offers a wide range of electrodes and accessories, such as thinner gauge electrodes with smaller ablation zones achieved with or without tine deployment, larger gauge electrodes with the ability to infuse saline to create a larger ablation zone, and various tine deployment configurations. With the RITA SDE, the tines deploy from the side of the electrode 1 cm from its tip, while the Boston Scientific Concerto uses both end and side tine deployment to create a bipolar device. Side deployment helps deal with difficult tine placement in mobile or extremely dense lesions, termed "push back," whereby the active tines are exposed proximal to the tumor or in close proximity to critical structures. Boston Scientific and RITA market coaxial systems as well. All systems incorporate the principles of temperature, impedance, and time and the feedback of all three to varying degrees to establish ablation end points. Currently, operators determine the RF system and electrode used, based on lesion size, geometry, location, access route, operator familiarity, and device availability. Algorithms for proper and thorough ablation also vary among the four manufacturers. The Boston Scientific system relies heavily on impedance, the RITA system on real-time temperature sensing, and the Valleylab system on time and end temperature. Procedural Considerations
Operators should situate the chosen electrode so as to ensure at least 1-cm margins around the entire target lesion, with multiple and overlapping ablations if needed (Figure 1). Ideally, for tumors measuring between 3 to 5 cm in diameter, six overlapping ablations should be performed-four in the axial plane and two along the z-axis-with all ablations coinciding at the tumor's center. It is critical to have CT documentation, using at least 5-mm collimation or thinner images through target lesion and electrode and tine positions, of electrode placement and, where appropriate, tine deployment with each ablation. Lencioni et al has demonstrated that multiplanar reformations can greatly aid and document accurate tine placement. Depending on the device selected, end points for each ablation are variable, as each system operates on different principles. Each manufacturer provides general algorithms and guidelines, but modification of these guidelines is allowable as the operator gains experience and familiarity with the device(s). The operator determines ablation completion, dependent on adequate margins of coverage, patient condition, and CT imaging end points, which include documentation of electrode position, tine deployment to establish adequate margins, and the presence of groundglass parenchymal change adjacent to areas of ablation and surrounding the targeted tumor in its entirety with 0.5-cm to 1-cm margins.[21,35] Once ablation of the entire tumor is achieved, the electrode is removed. Tract ablation is recommended but not necessary. A final series of images is obtained to evaluate for any acute complications. If detected, small pneumothoraces may be observed or aspirated, while large pneumothoraces may require placement of an evacuation catheter. Each case should be thoroughly documented, and documentation will vary for each device used. Data forms should specify type of device including electrode used, deployment size, maximum power, average target temperature, number of ablations, tract ablation, and the presence and/or treatment of complications, if any. Immediate postprocedural care involves noninvasive monitoring, pain control, and assessment of potential complications through physician and nurse assessment and postprocedural chest radiographs. Generally, an expiratory chest radiograph should be obtained within the first 2 hours of the procedure, with a second one obtained between 3 and 4 hours after the procedure. Following assessment of the second chest radiograph and examination, the patient may be discharged home. Depending on the patient's clinical course and assessment, the operator will determine whether limited or overnight admission for observation is required. Complications
Both reported complications and complication rates related to RF lung ablation have been rather variable, but overall rates of morbidity and mortality are extremely low. Complications are related to electrode placement and the delivery of RF energy. These include prolonged pain following ablation,[ 20] hemoptysis and pulmonary hemorrhage, pneumonia and abscess,[ 22] pleural effusion, pneumothorax requiring observation and/or evacuation, bronchopleural fistula, cerebral air embolism,[38,39] acute respiratory distress syndrome and death,[19,21,37] inability to retract electrode tines, and electrode tract and pleural tumor seeding. Specific complications related to the delivery of RF energy include dispersive electrode or grounding pad skin burns and interference with coand/ or preexisting medical devices. Lung ablation patients also exhibit a postablation syndrome similar to that described in patients posthepatic tumor ablation, consisting of lowgrade fevers and malaise, with productive cough with brown or rustcolored expectorant and dyspnea, particularly in the severe lung disease population. Complications have been reported in up to 76% of patients, most of them minor postablation-type symptoms, pneumothoraces, and pleural effusions. Pneumothorax rates have ranged from 4.2% to 53.8%, and those requiring evacuation with pleural catheter or thoracostomy tube from 7.2% to 25%. The occurrence of pleural effusions has been reported as 3.7% to 52.4%. Other complications have been sporadically reported with incidence rates at 10% or less. At least three deaths have been reported, the first due to lethal pulmonary hemorrhage in a patient on a commonly used antiplatelet drug, clopidogrel (Plavix), the second related to Acute Respiratory Distress Syndrome 4 days following the RF procedure, and the third as result of hemoptysis 19 days following RFA of a central tumor.